Uptake of ochratoxin A by slices of pig kidney cortex

Evaluation of renal in vitro models used in ochratoxin research

Ochratoxin A (OTA) induces renal carcinomas in rodents with a specific localisation in the S3 segment of proximal tubules and distinct early severe tissue alterations, which have been observed also in other species. Pronounced species- and sex-specific differences in toxicity occur and similar effects cannot be excluded in humans, however precise mechanism(s) remain elusive until today. In such cases, the use of in vitro models for mechanistic investigations can be very useful; in particular if a non-genotoxic mechanism of cancer formation is assumed which include cytotoxic effects. However, potential genotoxic mechanisms can also be investigated in vitro. A crucial issue of in vitro research is the choice of the appropriate cell model. Apparently, the cellular target of OTA is the renal proximal tubular cell; therefore cells from this tissue area are the most reasonable model. Furthermore, cells from affected species should be used and can be compared to cells of human origin. Another important parameter is whether to use primary cultures or to choose a cell line from the huge variety of cell lines available. In any case, important characteristics and quality controls need to be verified beforehand. Therefore, this review discusses the renal in vitro models that have been used for the investigation of renal ochratoxin toxicity. In particular, we discuss the choice of the models and the essential parameters making them suitable models for ochratoxin research together with exemplary results from this research. Furthermore, new promising models such as hTERT-immortalised cells and 3D-cultures are briefly discussed.

Molecular mechanism of ochratoxin a transport in the kidney

The mycotoxin, ochratoxin A (OTA), is thought to be responsible for Balkan endemic nephropathy. OTA accumulates in several tissues, especially in the kidneys and liver. The excretion of OTA into urine is thought to be mainly by tubular secretion, presumably via the organic anion transport system. Recently, several families of multispecific organic anion transporters have been identified: organic anion transporters (OATs), organic anion-transporting polypeptides (OATPs), oligopeptide transporters (PEPTs), and ATP-binding cassette (ABC) transporters, such as MRP2 and BCRP. These renal transporters mediate the transmembrane transport of OTA and play a pivotal role in the development of OTA-induced nephrotoxicity.

Renal transepithelial secretion of ochratoxin A in the non-filtering toad kidney

Renal excretion is an important way of elimination for the nephrotoxin ochratoxin A (OTA). Because binding to proteins hinders filtration, excretion is mainly due to proximal tubular secretion. The goal of this study was to investigate the kinetics of secretion as well as the extent of urine and tissue accumulation in situ using the non-filtering amphibian kidney model. Transepithelial secretion is a saturable process (K(m) = 0.63.10(-6) mol/l) and leads to a concentration-dependent accumulation of OTA in the tubular lumen and in renal tissue. Maximum accumulation achieved is approximately 14-fold as compared to the perfusate concentration. There was no accumulation in the tubular lumen as compared to renal tissue (lumen-to-tissue concentration ratio approximately 1). Tissue and tubular lumen accumulation were reduced to approximately 40% of control in the presence of 10(-3) mol/l p-aminohippurate (PAH). Addition of 10(-3) mol/l alpha-ketoglutarate (KG) to PAH-containing perfusate did not lead to a further reduction of secretion. By contrast, addition of 10(-2) mol/l L-phenylalanine (L-Phe) reduced secretion further to approximately 25% of control. In the presence of 10(-3) mol/l probenecid tissue accumulation was reduced to 7% and tubular lumen accumulation to 1% of control. Lumen-to-tissue concentration ratio decreased to 0.15 in the presence of probenecid, indicating an inhibitory action at the luminal membrane. Addition of albumin to the perfusate, reduced secretion to only 50% of control, whereas the concentration of free OTA was reduced below 1% as compared to control. The results of this study show that transepithelial secretion is an effective way for accumulation of OTA in the tubular lumen and thus its urinary excretion. Transport via the basolateral organic anion and a basolateral amino acid carrier are the active steps in transepithelial secretion. Luminal exit of OTA is a passive process. Furthermore, tissue accumulation by the active transport across the basolateral membrane supports the toxic action of OTA on proximal tubular cells. Due to the qualitative similarity of organic anion transport our findings should also apply for the mammalian kidney.